• IDO1 inhibition: The phase III ECHO-301/KEYNOTE-252 trial of epacadostat plus pembrolizumab in melanoma was negative, and no IDO1-targeting regimen has produced a positive efficacy signal in glioblastoma. The gene discussed is IDO1; the disease is melanoma.